tiprankstipranks
Advertisement
Advertisement

Starcoin Advances Bond Restructuring and Funding Plans After Audit Disclaimer

Story Highlights
  • Starcoin is pursuing bond restructuring, funding initiatives, and cost controls to address a prior going-concern audit disclaimer and stabilise its finances.
  • The company extended terms on its HK$715 million Extrawell convertible bonds and is exploring a share subscription to offset this debt while seeking additional financing.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Starcoin Advances Bond Restructuring and Funding Plans After Audit Disclaimer

Claim 55% Off TipRanks

An announcement from Innovative Pharmaceutical Biotech ( (HK:0399) ) is now available.

Starcoin Group Limited has issued an update on efforts to address a prior audit disclaimer of opinion related to its ability to continue as a going concern, outlining progress on bond restructuring, capital raising, and cost controls. The company remains under scrutiny after its auditor declined to provide a clean opinion on the financial statements for the year ended 31 March 2025, and it is using these measures to stabilise its balance sheet and reassure stakeholders.

A key focus is the HK$715 million Extrawell Convertible Bonds, for which Starcoin has signed a fourth deed of amendment with Extrawell Pharmaceutical Holdings and extended the long stop date to 30 June 2026, while also postponing the shareholder circular to late May. The company has additionally signed a non-binding memorandum of understanding with Marvel Nice Limited for a possible share subscription to be settled by offsetting the bonds and accrued interest, and continues to seek new equity or debt funding while tightening cost controls to improve profitability and cash flow.

The most recent analyst rating on (HK:0399) stock is a Sell with a HK$0.12 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.

More about Innovative Pharmaceutical Biotech

Starcoin Group Limited, formerly known as Innovative Pharmaceutical Biotech Limited, is a Hong Kong-listed company engaged in businesses that have included pharmaceutical and biotech-related activities. The group operates through various subsidiaries and has historically relied on capital market instruments such as sizable convertible bond issuances to support its operations and financing needs.

Average Trading Volume: 42,850,536

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$399.8M

For detailed information about 0399 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1